Search

Your search keyword '"Passamonti, F."' showing total 798 results
Start Over Author "Passamonti, F."
798 results on '"Passamonti, F."'

154. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

Author

Passamonti, F., primary, Rumi, E., additional, Arcaini, L., additional, Boveri, E., additional, Elena, C., additional, Pietra, D., additional, Boggi, S., additional, Astori, C., additional, Bernasconi, P., additional, Varettoni, M., additional, Brusamolino, E., additional, Pascutto, C., additional, and Lazzarino, M., additional

Published
2008
Full Text
View/download PDF

157. Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

Author

Gugliotta, Luigi, primary, Bulgarelli, S., primary, Asioli, S., primary, Tieghi, A., primary, Gardini, G., primary, Sabattini, E., primary, Franco, V., primary, Boveri, E., primary, Kvasnicka, H. M., primary, Vianelli, N., primary, Candoni, A., primary, Latagliata, R., primary, Passamonti, F., primary, Rupoli, S., primary, Martinelli, V., primary, Zaccaria, A., primary, Lauria, F., primary, De Biasi, E., primary, Sacchi, S., primary, Gobbi, M., primary, Tabilio, A., primary, Cacciola, E., primary, Cacciola, R., primary, Grossi, A., primary, Mazza, P., primary, Bonifazi, F., primary, Favini, P., primary, Mandelli, F., primary, Baccarani, M., primary, and Thiele, J., primary

Published
2005
Full Text
View/download PDF

158. PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.

Author

Gugliotta, Luigi, primary, Bulgarelli, S., additional, Vianelli, N., additional, Russo, D., additional, Candoni, A., additional, Rupoli, S., additional, Latagliata, R., additional, Sacchi, S., additional, Martinelli, V., additional, De Biasi, E., additional, Bucalossi, A., additional, Mazzotta, S., additional, Tabilio, A., additional, Passamonti, F., additional, Grossi, A., additional, Cacciola, E., additional, Cacciola, R., additional, Pogliani, E., additional, Bonifazi, F., additional, Fanin, R., additional, Leoni, P., additional, Mandelli, F., additional, Zaccaria, A., additional, Lauria, F., additional, Lazzarino, M., additional, Gobbi, M., additional, Bosi, A., additional, Mazza, P., additional, Fincato, G., additional, Favini, P., additional, and Baccarani, M., additional

Published
2005
Full Text
View/download PDF

159. Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.

Author

Gugliotta, L., primary, Bulgarelli, S., additional, Tieghi, A., additional, Asioli, S., additional, Gardini, G., additional, Vianelli, N., additional, Candoni, A., additional, Latagliata, R., additional, Rupoli, S., additional, Martinelli, V., additional, Zaccaria, A., additional, De Biasi, E., additional, Sacchi, S., additional, Lauria, F., additional, Miglino, M., additional, Passamonti, F., additional, Tabilio, A., additional, Cacciola, E., additional, Grossi, A., additional, Pisapia, G., additional, Favini, P., additional, and Baccarani, M., additional

Published
2004
Full Text
View/download PDF

163. Epidemiological Survey on Equine Cryptosporidium and Giardia Infections in Italy and Molecular Characterization of Isolates F. Veronesi et al. Epidemiological Survey on Equine Infections and its Molecular Characterization.

Author

Veronesi, F., Passamonti, F., Cacciò, S., Diaferia, M., and Piergili Fioretti, D.

Subjects
*HORSE infections, *CRYPTOSPORIDIOSIS, *GIARDIASIS, *EPIDEMIOLOGICAL research, *CRYPTOSPORIDIUM, *GIARDIA, *MICROBIOLOGY, *FECES, *ZOONOSES
Abstract

Cryptosporidium and Giardia are two of the most common enteric pathogens of domestic and wild animals and humans. However, little is known on the prevalence, clinical manifestations and economic and zoonotic significance of these infections in horses. This study was undertaken to investigate the prevalence, excretion patterns and risk factors related to the faecal shedding of Cryptosporidium oocysts and Giardia cysts in horses and the zoonotic potential of species/genotypes isolated. The survey was performed on 120 foals and 30 broodmares reared in five Italian farms. Foals were divided in four homogeneous groups of 30 animals each (age classes: 0-2, 2-4, 4-8, >8 weeks). Three sequential faecal samples were collected from each animal and analysed by three techniques: direct fluorescent antibody test (DFA), faecal flotation (FF) and stained faecal smears (SFS). The DFA results showed a prevalence of 8% for Cryptosporidium and of 13.33% for Giardia; the prevalence values obtained by FF and SFS were lower and in poor agreement with DFA results. Giardia and Cryptosporidium infections were more common in foals (23.33% and 26.66% respectively) and higher excretions were observed in the youngest foals. Distribution of Cryptosporidium prevalence was statistically related to farms ( P < 0.01), age of animals ( P < 0.01), but was unrelated to the presence of diarrhoea. In the case of Giardia, the prevalence was only related to age ( P < 0.01). Pattern sheddings were related to intestinal diseases and horse age ( P < 0.01). Risk factors for shedding included residence farms and age older than 8 weeks for both parasites. All DFA-positive faecal samples were submitted to DNA extraction and PCR to determine Giardia and Cryptosporidium species/genotypes. Sequence analysis of the COWP gene of Cryptosporidium and of the SSU-rRNA gene of Giardia revealed that they were identical to each other and identified Cryptosporidium parvum and Giardia duodenalis assemblage E. The potential role of infected horses in zoonotic transmission of Cryptosporidium was supported by the findings of this study. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

168. Septic pyomyositis, multiple pelvic osteomyelitis and thrombosis in a Thoroughbred foal.

Author

Pressanto, M. C., Beccati, F., Stefanetti, V., Passamonti, F., Pilati, N., and Pepe, M.

Subjects
FOALS, OSTEOMYELITIS, THROMBOSIS, STREPTOCOCCUS equi, ILIAC artery, GLUTEAL muscles, INFECTIOUS arthritis, VETERINARY autopsy
Abstract

Summary: Multiple septic osteomyelitis, septic thrombi and septic arthritis are recognised as possible complications of sepsis; however, there are few reports of localised pyomyositis in association with septic arterial thrombosis in foals. A 1‐month Thoroughbred colt was presented for investigation of acute and progressive left hindlimb lameness. Physical and laboratory examinations were performed. Ultrasonographic, radiographic and computed tomographic examinations revealed the presence of multiple abscesses and areas of osteomyelitis localised to the gluteal muscles, coxal bone and lumbar spine respectively. Considering the poor prognosis, the foal was subjected to euthanasia. Necropsy confirmed the diagnostic imaging findings and revealed the presence of an extensive septic thrombus, affecting the internal iliac artery, and a single pulmonary abscess. Streptococcus equi subsp. zooepidemicus was isolated from all lesions. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

178. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders

Author

Passamonti, F., Vanelli, L., Malabarba, L., Rumi, E., Pungolino, E., LUCA MALCOVATI, Pascutto, C., Morra, E., Lazzarino, M., and Cazzola, M.

Subjects
Adult, Aged, 80 and over, Male, Myeloproliferative Disorders, Adolescent, Antigens, CD34, Cell Count, Essential thrombocythemia, Middle Aged, Hematopoietic Stem Cells, Cross-Sectional Studies, Primary Myelofibrosis, polycythemia myelofibrosis, CD34, Humans, Female, Longitudinal Studies, Prospective Studies, Polycythemia Vera, Biomarkers, Aged, Thrombocythemia, Essential
Abstract

Flow cytometry enumeration of peripheral blood CD34-positive cells provides reliable measurements of circulating hematopoietic progenitors in humans. Since the absolute number of circulating CD34-positive cells has been previously found to be elevated in myelofibrosis with myeloid metaplasia (MMM), we prospectively studied the clinical utility of this parameter in the work-up of patients with chronic myeloproliferative disorders.Of the 248 consecutive patients enrolled in this study, 106 had polycythemia vera (PV), 90 essential thrombocythemia (ET), and 52 myelofibrosis with myeloid metaplasia (MMM). The study population included both newly diagnosed and established cases, and of these latter some patients were on cytoreductive treatment while others were chemotherapy naive. Both cross-sectional and longitudinal investigations were carried out. Flow cytometry enumeration of CD34-positive cells was performed using a single-platform assay.Median numbers and ranges of circulating CD34-positive cells were 2.3x10(6)/L (0-5) in 20 control subjects, 2.2x10(6)/L (0-14) in those with PV, 2.4x10(6)/L (0-14) in those with ET, and 114x10(6)/L (6-2,520) in MMM patients. Analysis of variance demonstrated that values were markedly higher in MMM patients than in the remaining groups, and counts did not appear to fluctuate over short periods of follow-up. In both cross-sectional and longitudinal investigations on patients at clinical onset and/or out of cytoreductive treatment, a CD34-positive count ofor = 15x10(6)/L was always associated with MMM, clearly indicating a disease-related specificity.The absolute number of circulating CD34-positive cells is normal or anyhow lower than 15x10(6)/L in patients with uncomplicated PV or ET, whereas it is equal or above this cut-off in those with MMM, likely reflecting abnormal hematopoietic progenitor cell trafficking. Thus, enumeration of circulating CD34-positive cells may be useful in the work-up of patients with myeloproliferative disorders.

180. CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY

Author

Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Caramazza, D., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Michele Merli, Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., and Passamonti, F.

181. RUXOLITINIB PROVES SUPERIOR TO BEST AVAILABLE THERAPY IN PATIENTS WITH POLYCYTHEMIA VERA (PV) AND A NONPALPABLE SPLEEN: RESULTS FROM THE PHASE IIIB RESPONSE-2 STUDY

Author

Passamonti, F., Griesshammer, M., FRANCESCA PALANDRI, Egyed, M., Benevolo, G., Devo, T., Callum, J., Vannucchi, A. M., Sivgin, S., Bensasson, C., Khan, M., Mounedji, N., Saydam, G., and Ege Üniversitesi

Subjects
population characteristics, social sciences, health care economics and organizations, geographic locations, humanities
Abstract

21st Congress of the European-Hematology-Association -- JUN 09-12, 2016 -- Copenhagen, DENMARK, WOS: 000379484600014, European Hematol Assoc

191. Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia

Author

Gugliotta, L., Bulgarelli, S., Vianelli, N., Russo, D., Gamberi, B., Candoni, A., Rupoli, S., Barulli, S., Latagliata, R., Frattarelli, N., Sacchi, S., Nerbano, S., Martinelli, V., Ciancia, R., Molinari, Al, Biasi, E., Bucalossi, A., Tabilio, A., Marcomigni, L., Passamonti, F., Miglino, M., Riccardo Varaldo, Grossi, A., Cacciola, E., Cacciola, R., Pisapia, G., Gentili, S., Pogliani, E., Fincato, G., and Baccarani, M.

Subjects
Thrombocythemia Interferon Peg Intron [Keywords]

193. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients

Author

Passamonti, F., Brusamolino, E., Lazzarino, M., Barate, C., Catherine Klersy, Orlandi, E., Canevari, A., Castelli, G., Merante, S., and Bernasconi, C.

Subjects
Adult, Aged, 80 and over, Male, Pipobroman, Time Factors, Treatment Outcome, Administration, Oral, Humans, Female, Middle Aged, Antineoplastic Agents, Alkylating, Polycythemia Vera, Aged
Abstract

Polycythemia vera (PV) is a myeloproliferative disorder, characterized by the expansion of the red cell mass. Our purpose was to evaluate the efficacy of pipobroman (PB) in the long-term control of PV and to assess early and late events.From June 1975 to December 1997, 163 untreated patients with PV (median age 57 years, range 30-82) were treated with PB in a single Institute for a median follow-up of 120 months. The diagnosis was made according to the Polycythemia Vera Study Group criteria. PB was given at the dose of 1 mg/kg/day until hematologic response (hematocrit45% and platelets400x109/L) and of 0.3-0.6 mg/kg/day as maintenance therapy.Hematologic remission was achieved in 94% of patients in a median time of 13 weeks (range 6-48). Median overall survival was 215 months, with a standardized mortality ratio of 1.7. The cumulative risk of death was 11%, 22%, and 26% at 7, 10, and 12 years, respectively. The incidence of thrombotic events was 18.4x105 person-year and the cumulative risk was 6%, 11%, 16%, and 20% at 3, 7, 10, and 12 years respectively. Acute leukemia occurred in 11 patients, myelofibrosis in 7, and solid tumors in 11. The 10-year cumulative risk of leukemia, myelofibrosis, and solid tumors was 5%, 4%, and 8%, respectively. In the logistic analysis age over 65 (p = 0.0001) and thrombotic events at diagnosis (p = 0.001) were significantly correlated with a higher risk of death. Female gender (p = 0.02) and age over 65 (p = 0.01) significantly influenced the occurrence of thrombotic complications. Age was the only significant risk factor for leukemia (p = 0.04) and for solid tumors (p = 0.03), while the duration of PB treatment did not influence these risks. No significant risk factor was demonstrated for myelofibrosis.This study demonstrates in a large series of patients, observed for a long period, that pipobroman is effective in the long-term control of PV. The risk of early thrombotic complications at 3 years is 6% and the 10-year risk of acute leukemia, late myelofibrosis, and solid tumors is 5%, 4%, and 8%, respectively. The duration of pipobroman treatment did not correlate with these events.

198. Ruxolitinib and survival improvement in patients with myelofibrosis.

Author

Passamonti, F, Vannucchi, A M, Cervantes, F, Harrison, C, Morra, E, Kantarjian, H, and Verstovsek, S

Subjects
*MYELOFIBROSIS, *PATIENT safety, *THERAPEUTICS
Abstract

A letter to the editor is presented in response to an article related to the use of ruxolitinib drug for the treatment of patients suffering from myelofibrosis, published in previous issue.

Published
2015
Full Text
View/download PDF

199. Cytogenetic and clinico-hematological correlations in 23 secondary AL and MDS

Author

Bernasconi, P., Campagnoli, C., Alessandrino, E.P., Boni, M., Astori, C., Passamonti, F., Troletti, D., and Bernasconi, C.

Subjects
Acute leukemia -- Research, Myelodysplastic syndromes -- Research, Human chromosome abnormalities -- Research, Health, Science and technology
Abstract

AUTHORS: P. Bernasconi, C. Campagnoli, E.P. Alessandrino, M. Boni, C. Astori, F. Passamonti, D. Troletti and C. Bernasconi. University of Pavia, Pavia, Italy. According to the authors' abstract of a [...]

Published
1992

200. Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Author

Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, McMullin, M F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, and Gale, R P

Abstract

Correction to: Leukemia advance online publication 18 November 2016; doi:10.1038/leu.2016.300 Following the online publication of this article, the authors noted that Dr McMullin was incorrectly excluded from the author list. The complete author names are given above. Dr McMullin’s affiliation is Department of Haematology, Queen’s University, Belfast, UK.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results